89 related articles for article (PubMed ID: 15650450)
21. Tumor stem cell antigens as consolidative active specific immunotherapy: a randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma.
Dillman RO; Cornforth AN; Depriest C; McClay EF; Amatruda TT; de Leon C; Ellis RE; Mayorga C; Carbonell D; Cubellis JM
J Immunother; 2012 Oct; 35(8):641-9. PubMed ID: 22996370
[TBL] [Abstract][Full Text] [Related]
22. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
23. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases.
Berd D; Sato T; Cohn H; Maguire HC; Mastrangelo MJ
Int J Cancer; 2001 Nov; 94(4):531-9. PubMed ID: 11745440
[TBL] [Abstract][Full Text] [Related]
24. Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells.
Matsumoto A; Haraguchi K; Takahashi T; Azuma T; Kanda Y; Tomita K; Kurokawa M; Ogawa S; Takahashi K; Chiba S; Kitamura T
Int J Urol; 2007 Apr; 14(4):277-83. PubMed ID: 17470153
[TBL] [Abstract][Full Text] [Related]
25. Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine.
Berd D; Sato T; Maguire HC; Kairys J; Mastrangelo MJ
J Clin Oncol; 2004 Feb; 22(3):403-15. PubMed ID: 14691123
[TBL] [Abstract][Full Text] [Related]
26. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
Ridolfi L; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Brolli C; Selva M; Scarpi E; Valmorri L; Nicoletti SV; Guidoboni M; Riccobon A; Ridolfi R
Melanoma Res; 2011 Dec; 21(6):524-9. PubMed ID: 21909041
[TBL] [Abstract][Full Text] [Related]
28. Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer.
Berger M; Kreutz FT; Horst JL; Baldi AC; Koff WJ
J Pharm Pharm Sci; 2007; 10(2):144-52. PubMed ID: 17706173
[TBL] [Abstract][Full Text] [Related]
29. Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia.
Tan YF; Sim GC; Habsah A; Leong CF; Cheong SK
Malays J Pathol; 2008 Dec; 30(2):73-9. PubMed ID: 19291915
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.
Fishman M; Hunter TB; Soliman H; Thompson P; Dunn M; Smilee R; Farmelo MJ; Noyes DR; Mahany JJ; Lee JH; Cantor A; Messina J; Seigne J; Pow-Sang J; Janssen W; Antonia SJ
J Immunother; 2008 Jan; 31(1):72-80. PubMed ID: 18157014
[TBL] [Abstract][Full Text] [Related]
31. Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N; Brawley VS; Hegde M; Robertson C; Ghazi A; Gerken C; Liu E; Dakhova O; Ashoori A; Corder A; Gray T; Wu MF; Liu H; Hicks J; Rainusso N; Dotti G; Mei Z; Grilley B; Gee A; Rooney CM; Brenner MK; Heslop HE; Wels WS; Wang LL; Anderson P; Gottschalk S
J Clin Oncol; 2015 May; 33(15):1688-96. PubMed ID: 25800760
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
Kyte JA; Mu L; Aamdal S; Kvalheim G; Dueland S; Hauser M; Gullestad HP; Ryder T; Lislerud K; Hammerstad H; Gaudernack G
Cancer Gene Ther; 2006 Oct; 13(10):905-18. PubMed ID: 16710345
[TBL] [Abstract][Full Text] [Related]
33. Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients.
Bedrosian I; Mick R; Xu S; Nisenbaum H; Faries M; Zhang P; Cohen PA; Koski G; Czerniecki BJ
J Clin Oncol; 2003 Oct; 21(20):3826-35. PubMed ID: 14551301
[TBL] [Abstract][Full Text] [Related]
34. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
35. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
36. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
Dessureault S; Noyes D; Lee D; Dunn M; Janssen W; Cantor A; Sotomayor E; Messina J; Antonia SJ
Ann Surg Oncol; 2007 Feb; 14(2):869-84. PubMed ID: 17103257
[TBL] [Abstract][Full Text] [Related]
37. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine: a safety study.
Ovali E; Dikmen T; Sonmez M; Yilmaz M; Unal A; Dalbasti T; Kuzeyli K; Erturk M; Omay SB
J Exp Clin Cancer Res; 2007 Jun; 26(2):209-14. PubMed ID: 17725100
[TBL] [Abstract][Full Text] [Related]
38. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.
Eton O; Ross MI; East MJ; Mansfield PF; Papadopoulos N; Ellerhorst JA; Bedikian AY; Lee JE
J Transl Med; 2010 Jan; 8():9. PubMed ID: 20109236
[TBL] [Abstract][Full Text] [Related]
39. A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903.
Posner MC; Niedzwiecki D; Venook AP; Hollis DR; Kindler HL; Martin EW; Schilsky RL; Goldberg RM; Mayer RJ
Ann Surg Oncol; 2008 Jan; 15(1):158-64. PubMed ID: 18008108
[TBL] [Abstract][Full Text] [Related]
40. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
